Mitsuyoshi Suzuki, Kei Minowa, Hitoshi Tajiri
Interferon-based simeprevir therapy showed high efficacy and tolerability in children with genotype 1 hepatitis C virus infection. While direct-acting antivirals (DAAs) therapy are undergoing study in children, this regimen is considered an available therapeutic option for selected patients in countries where DAAs have not yet been approved.
Key words. Peginterferon, Ribavirin, Direct-acting antivirals, Hyperbilirubinemia, Shorter treatment time